These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9829366)

  • 1. Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease.
    van Dullemen HM; Wolbink GJ; Wever PC; van der Poll T; Hack CE; Tytgat GN; van Deventer SJ
    Scand J Gastroenterol; 1998 Oct; 33(10):1094-8. PubMed ID: 9829366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
    Pruzanski W; Urowitz MB; Grouix B; Vadas P
    J Rheumatol; 1995 Oct; 22(10):1816-9. PubMed ID: 8991975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
    van Dullemen HM; van Deventer SJ; Hommes DW; Bijl HA; Jansen J; Tytgat GN; Woody J
    Gastroenterology; 1995 Jul; 109(1):129-35. PubMed ID: 7797011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis.
    Arbibe L; Vial D; Rosinski-Chupin I; Havet N; Huerre M; Vargaftig BB; Touqui L
    J Immunol; 1997 Jul; 159(1):391-400. PubMed ID: 9200478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes.
    Bidgood MJ; Jamal OS; Cunningham AM; Brooks PM; Scott KF
    J Immunol; 2000 Sep; 165(5):2790-7. PubMed ID: 10946311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy with interleukin-2 induces the systemic release of phospholipase-A2.
    Wolbink GJ; Schalkwijk C; Baars JW; Wagstaff J; van den Bosch H; Hack CE
    Cancer Immunol Immunother; 1995 Nov; 41(5):287-92. PubMed ID: 8536274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible Involvement of Intracellular Calcium-Independent Phospholipase A
    Christerson U; Keita ÅV; Winberg ME; Söderholm JD; Gustafson-Svärd C
    Cells; 2019 Jul; 8(7):. PubMed ID: 31277247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule depolymerization selectively down-regulates the synthesis of proinflammatory secretory nonpancreatic phospholipase A2.
    Pruzanski W; Kennedy BP; van den Bosch H; Stefanski E; Vadas P
    Lab Invest; 1997 Feb; 76(2):171-8. PubMed ID: 9042153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Functional analysis of phospholipase A2 receptor by gene knockout studies].
    Yokota Y
    Yakugaku Zasshi; 2001 Jan; 121(1):23-33. PubMed ID: 11201160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OKT3-induced nephrotoxicity is associated with release of group II secretory phospholipase A2.
    Wever PC; Roest RW; Wolbink-Kamp AM; Wolbink GJ; Weening JJ; Hack CE; ten Berge JM
    Eur J Clin Invest; 1996 Oct; 26(10):873-8. PubMed ID: 8911860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.
    Snyder DW; Bach NJ; Dillard RD; Draheim SE; Carlson DG; Fox N; Roehm NW; Armstrong CT; Chang CH; Hartley LW; Johnson LM; Roman CR; Smith AC; Song M; Fleisch JH
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1117-24. PubMed ID: 10027849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease.
    Urra JM; Arteta M; Gómez-Caturla A; García-Durán F
    Hum Antibodies; 2001; 10(2):91-4. PubMed ID: 11673664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by unsaturated fatty acids of type II secretory phospholipase A2 synthesis in guinea-pig alveolar macrophages evidence for the eicosanoid-independent pathway.
    Alaoui El Azher M; Havet N; Singer M; Dumarey C; Touqui L
    Eur J Biochem; 2000 Jun; 267(12):3633-9. PubMed ID: 10848980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.
    Minami T; Tojo H; Shinomura Y; Tarui S; Okamoto M
    Gut; 1992 Jul; 33(7):914-21. PubMed ID: 1644331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated group II phospholipase A2 mass concentration in serum and colonic mucosa in Crohn's disease.
    Haapamäki MM; Grönroos JM; Nurmi H; Söderlund K; Peuravuori H; Alanen K; Nevalainen TJ
    Clin Chem Lab Med; 1998 Oct; 36(10):751-5. PubMed ID: 9853800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease.
    Hommes DW; van Dullemen HM; Levi M; van der Ende A; Woody J; Tytgat GN; van Deventer SJ
    Haemostasis; 1997; 27(6):269-77. PubMed ID: 9731107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
    Pruzanski W; Stefanski E; Vadas P; Ramamurthy NS
    Biochem Pharmacol; 1997 Jun; 53(12):1901-7. PubMed ID: 9256165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies targeting tumor necrosis factor in Crohn's disease.
    Sandborn WJ
    Acta Gastroenterol Belg; 2001; 64(2):170-2. PubMed ID: 11475128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans.
    van der Poll T; Coyle SM; Levi M; Jansen PM; Dentener M; Barbosa K; Buurman WA; Hack CE; ten Cate JW; Agosti JM; Lowry SF
    Blood; 1997 May; 89(10):3727-34. PubMed ID: 9160678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.